skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 20,124  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Material Type:
Article 		Add to My Research

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Cancer science, 2016-09, Vol.107 (9), p.1179-1186 [Peer Reviewed Journal]

2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ;2016. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1347-9032 ;EISSN: 1349-7006 ;DOI: 10.1111/cas.12996 ;PMID: 27323238

Full text available

Citations Cited by
2
A retrospective study of the eGFR differences between the 2021 CKD-EPI Equation and the MDRD equation in Black and White Patients
A retrospective study of the eGFR differences between the 2021 CKD-EPI Equation and the MDRD equation in Black and White Patients
Material Type:
Article 		Add to My Research

A retrospective study of the eGFR differences between the 2021 CKD-EPI Equation and the MDRD equation in Black and White Patients

American journal of clinical pathology, 2022-11, Vol.158 (Supplement_1), p.S27-S27 [Peer Reviewed Journal]

American Society for Clinical Pathology, 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022 ;American Society for Clinical Pathology, 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com ;ISSN: 0002-9173 ;EISSN: 1943-7722 ;DOI: 10.1093/ajcp/aqac126.048

Full text available

Citations Cited by
3
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Material Type:
Article 		Add to My Research

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

Nature reviews. Clinical oncology, 2022-08, Vol.19 (8), p.499-514 [Peer Reviewed Journal]

Springer Nature Limited 2022. corrected publication 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;ISSN: 1759-4774 ;EISSN: 1759-4782 ;DOI: 10.1038/s41571-022-00639-9 ;PMID: 35534623

Full text available

Citations Cited by
4
Author Correction: GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth
Author Correction: GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth
Material Type:
Article 		Add to My Research

Author Correction: GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth

Scientific reports, 2020-05, Vol.10 (1), p.7675-7675, Article 7675 [Peer Reviewed Journal]

The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-020-64604-1 ;PMID: 32355321

Full text available

Citations Cited by
5
Publisher Correction: Revealing membrane alteration in cells overexpressing CA IX and EGFR by Surface-Enhanced Raman Scattering
Publisher Correction: Revealing membrane alteration in cells overexpressing CA IX and EGFR by Surface-Enhanced Raman Scattering
Material Type:
Article 		Add to My Research

Publisher Correction: Revealing membrane alteration in cells overexpressing CA IX and EGFR by Surface-Enhanced Raman Scattering

Scientific reports, 2019-06, Vol.9 (1), p.9001-1, Article 9001 [Peer Reviewed Journal]

2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-019-45208-w ;PMID: 31209245

Full text available

Citations Cited by
6
AB0422 THE EFFECTS OF CONCOMITANT USE OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SARILUMAB
AB0422 THE EFFECTS OF CONCOMITANT USE OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SARILUMAB
Material Type:
Article 		Add to My Research

AB0422 THE EFFECTS OF CONCOMITANT USE OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SARILUMAB

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1399-1399 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1920

Full text available

Citations Cited by
7
Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
Material Type:
Article 		Add to My Research

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure

Cancer science, 2016-07, Vol.107 (7), p.1001-1005 [Peer Reviewed Journal]

2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ;2016. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1347-9032 ;EISSN: 1349-7006 ;DOI: 10.1111/cas.12963 ;PMID: 27145431

Full text available

Citations Cited by
8
EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
Material Type:
Article 		Add to My Research

EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas

The journal of clinical endocrinology and metabolism, 2021-02, Vol.106 (2), p.e917-e925 [Peer Reviewed Journal]

The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020 ;The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. ;COPYRIGHT 2021 Oxford University Press ;The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com ;ISSN: 0021-972X ;EISSN: 1945-7197 ;DOI: 10.1210/clinem/dgaa805 ;PMID: 33150390

Full text available

Citations Cited by
9
Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
Material Type:
Article 		Add to My Research

Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation

Scientific reports, 2021-01, Vol.11 (1), p.2693-2693, Article 2693 [Peer Reviewed Journal]

The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-020-80901-1 ;PMID: 33495507

Full text available

Citations Cited by
10
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
Material Type:
Article 		Add to My Research

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

Nature chemical biology, 2021-09, Vol.17 (9), p.937-946 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer Nature America, Inc. part of Springer Nature 2021. ;ISSN: 1552-4450 ;EISSN: 1552-4469 ;DOI: 10.1038/s41589-021-00770-1 ;PMID: 33767387

Full text available

Citations Cited by
11
EGFR as a clinical marker in glioblastomas and other gliomas
EGFR as a clinical marker in glioblastomas and other gliomas
Material Type:
Article 		Add to My Research

EGFR as a clinical marker in glioblastomas and other gliomas

The International Journal of Biological Markers, 2018-01, Vol.33 (1), p.22-32 [Peer Reviewed Journal]

The Author(s) 2017 ;The Author(s) 2017. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content ;ISSN: 1724-6008 ;ISSN: 0393-6155 ;EISSN: 1724-6008 ;DOI: 10.5301/ijbm.5000301 ;PMID: 28885661

Full text available

Citations Cited by
12
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
Material Type:
Article 		Add to My Research

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial

Annals of the rheumatic diseases, 2019-03, Vol.78 (3), p.399-405 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;ISSN: 1468-2060 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-214245 ;PMID: 30612116

Full text available

Citations Cited by
13
Mechanical disruption of E-cadherin complexes with epidermal growth factor receptor actuates growth factor-dependent signaling
Mechanical disruption of E-cadherin complexes with epidermal growth factor receptor actuates growth factor-dependent signaling
Material Type:
Article 		Add to My Research

Mechanical disruption of E-cadherin complexes with epidermal growth factor receptor actuates growth factor-dependent signaling

Proceedings of the National Academy of Sciences - PNAS, 2022-01, Vol.119 (4), p.1 [Peer Reviewed Journal]

Copyright © 2022 the Author(s). Published by PNAS. ;Copyright National Academy of Sciences Jan 25, 2022 ;Copyright © 2022 the Author(s). Published by PNAS. 2022 ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.2100679119 ;PMID: 35074920

Full text available

Citations Cited by
14
The global burden of chronic kidney disease
The global burden of chronic kidney disease
Material Type:
Article 		Add to My Research

The global burden of chronic kidney disease

The Lancet (British edition), 2020-02, Vol.395 (10225), p.662-664 [Peer Reviewed Journal]

2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)32977-0 ;PMID: 32061314

Full text available

Citations Cited by
15
Empagliflozin in Patients with Chronic Kidney Disease
Empagliflozin in Patients with Chronic Kidney Disease
Material Type:
Article 		Add to My Research

Empagliflozin in Patients with Chronic Kidney Disease

The New England journal of medicine, 2023-01, Vol.388 (2), p.117-127 [Peer Reviewed Journal]

Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2023 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2204233 ;PMID: 36331190

Full text available

Citations Cited by
16
Clinical Impact of the Refit CKD-EPI 2021 Creatinine-Based eGFR Equation
Clinical Impact of the Refit CKD-EPI 2021 Creatinine-Based eGFR Equation
Material Type:
Article 		Add to My Research

Clinical Impact of the Refit CKD-EPI 2021 Creatinine-Based eGFR Equation

Clinical chemistry (Baltimore, Md.), 2022-03, Vol.68 (4), p.534-539 [Peer Reviewed Journal]

American Association for Clinical Chemistry 2022. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2022 ;American Association for Clinical Chemistry 2022. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0009-9147 ;EISSN: 1530-8561 ;DOI: 10.1093/clinchem/hvab282 ;PMID: 35038721

Full text available

Citations Cited by
17
New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race
New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race
Material Type:
Article 		Add to My Research

New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race

The New England journal of medicine, 2021-11, Vol.385 (19), p.1737-1749 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2102953 ;PMID: 34554658

Full text available

Citations Cited by
18
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Material Type:
Article 		Add to My Research

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2019-07, Vol.20 (7), p.924-937 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30167-6 ;PMID: 31122901

Full text available

Citations Cited by
19
Display of GPI‐anchored anti‐EGFR nanobodies on extracellular vesicles promotes tumour cell targeting
Display of GPI‐anchored anti‐EGFR nanobodies on extracellular vesicles promotes tumour cell targeting
Material Type:
Article 		Add to My Research

Display of GPI‐anchored anti‐EGFR nanobodies on extracellular vesicles promotes tumour cell targeting

Journal of extracellular vesicles, 2016-01, Vol.5 (1), p.31053-n/a [Peer Reviewed Journal]

2016 Sander A. A. Kooijmans et al. ;Copyright Co-Action Publishing 2016 ;Copyright Taylor & Francis Ltd. 2016 ;2016 Sander A. A. Kooijmans et al. 2016 ;ISSN: 2001-3078 ;EISSN: 2001-3078 ;DOI: 10.3402/jev.v5.31053 ;PMID: 26979463

Full text available

Citations Cited by
20
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Material Type:
Article 		Add to My Research

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening

Nature communications, 2019-09, Vol.10 (1), p.3991-15, Article 3991 [Peer Reviewed Journal]

2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-019-11867-6 ;PMID: 31488816

Full text available

Citations Cited by

Results 1 - 20 of 20,124  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (18,471)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1987  (17)
  2. 1987 To 1995  (301)
  3. 1996 To 2004  (884)
  4. 2005 To 2014  (4,178)
  5. After 2014  (14,724)
  6. More options open sub menu

Subject 

  1. Science & Technology  (17,214)
  2. Life Sciences & Biomedicine  (14,264)
  3. Epidermal Growth Factor Receptors  (13,176)
  4. Humans  (10,970)
  5. Oncology  (6,409)
  6. Epidermal Growth Factor  (6,220)
  7. Female  (5,826)
  8. Epidermal Growth Factor Receptor  (5,283)
  9. Mutation  (4,956)
  10. Male  (4,883)
  11. Tumors  (4,681)
  12. Patients  (4,393)
  13. Kinases  (4,284)
  14. Lung Cancer  (4,036)
  15. Middle Aged  (3,896)
  16. Cancer  (3,408)
  17. Aged  (3,391)
  18. Glomerular Filtration Rate  (3,209)
  19. Proteins  (3,163)
  20. Animals  (2,971)
  21. More options open sub menu

Language 

  1. English  (19,883)
  2. Japanese  (3,173)
  3. Chinese  (200)
  4. Korean  (25)
  5. Portuguese  (22)
  6. German  (15)
  7. French  (14)
  8. Russian  (13)
  9. Norwegian  (13)
  10. Polish  (7)
  11. Spanish  (6)
  12. Persian  (2)
  13. Turkish  (2)
  14. Italian  (1)
  15. Croatian  (1)
  16. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait